Amgen NESP
Executive Summary
Panel of arbitrators affirms Amgen has sole rights to novel erythropoiesis stimulating protein. Johnson & Johnson claimed it had rights to NESP under a 1985 licensing agreement giving it rights to erythropoetin (Epogen/Procrit) for non-dialysis uses in the U.S. and all uses worldwide. As a result of the binding arbitration decision, Amgen can develop and market NESP worldwide for all indications